42579-3 |
Aspergillus fumigatus Ab.IgM |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Aspergillus fumigatus IgM Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42579-3 |
|
|
|
|
Both |
|
|
|
0 |
A fumigatus IgM Ser-aCnc |
|
|
|
N |
|
A fumigatus; ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; Farmers lung; Fum; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; m003; m3; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
2.16 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
4258-0 |
Flunitrazepam |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Flunitrazepam [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4258-0 |
|
|
|
|
Observation |
|
|
|
0 |
Flunitrazepam Dose |
|
|
|
Y |
|
Darkene; Dose med or substance; DRUG DOSES; Hypnodorm; Hypnor; Narcozep; Noriel; Point in time; QNT; Quan; Quant; Quantitative; Random; Rohipnol; Rohypnol; Roipnol; Valsera |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42580-1 |
Babesia sp Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Babesia sp IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42580-1 |
|
|
|
|
Both |
|
|
|
0 |
Babesia IgM Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Babesiosis; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Piroplasmosis; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; species; spp; SR |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42581-9 |
Babesia sp Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Babesia sp IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42581-9 |
|
|
|
|
Both |
|
|
|
0 |
Babesia IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Babesiosis; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Piroplasmosis; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; species; spp; SR |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42582-7 |
Barbiturates |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Barbiturates [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
42582-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Barbiturates Bld Cfm-mCnc |
|
|
|
N |
|
Addiction; Barb; Barbiturate; Barbs; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
42583-5 |
Bean string Ab.IgE.RAST class |
PrThr |
Ser |
Pt |
Ord |
|
|
DEPRECATED |
Deprecated Bean string IgE Ab RAST class [Presence] in Serum |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
42583-5 |
|
|
|
|
Observation |
|
|
|
0 |
Deprecated Bean string IgE RAST Ql |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Beans; IgE RAST; Immune globulin E; Immunoglobulin E; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.75 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42584-3 |
Beet Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Beet IgG Ab [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
ALLERGY |
|
42584-3 |
|
|
|
|
Both |
|
|
|
0 |
Beet IgG-mCnc |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Immune globulin G; Immunoglobulin G; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
2.16 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
42585-0 |
Bendiocarb |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Bendiocarb [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42585-0 |
|
|
|
|
Both |
|
|
|
0 |
Bendiocarb Ur Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Ficam; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42586-8 |
Benzodiazepines |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Benzodiazepines [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
42586-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Benzodiaz Bld Cfm-mCnc |
|
|
|
N |
|
Benz; Benzodiaz; Benzodiazepine; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
42587-6 |
BK virus DNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
BK virus DNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42587-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
BKV DNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; BKV; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.73 |
2.16 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
42588-4 |
Bordetella parapertussis DNA |
PrThr |
Nph |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Bordetella parapertussis DNA [Presence] in Nasopharynx by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42588-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
B parapert DNA Nph Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B parapert; B parapertussis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nasopharynx; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Whooping cough |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42589-2 |
Borrelia burgdorferi DNA |
PrThr |
Body fld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Borrelia burgdorferi DNA [Presence] in Body fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42589-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
B burgdor DNA Fld Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B burg; B burgdor; B burgdorferi; B/F; Bb; BF; bod; Bodies; Body fluid; Body fluid, unsp; Burgdorf; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Fl; Fld; FLU; Fluid; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Lyme disease; Lymes; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4259-8 |
Fluorouracil |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Fluorouracil [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4259-8 |
|
|
|
|
Observation |
|
|
|
0 |
Fluorouracil Dose |
|
|
|
Y |
|
5FU; Dose med or substance; DRUG DOSES; Efudex; FU; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42590-0 |
Borrelia sp Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Borrelia sp Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42590-0 |
|
|
|
|
Both |
|
|
|
0 |
Borrelia Ab Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Microbiology; Point in time; Random; Relapsing fever; Serum; SmQn; species; spp; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
42591-8 |
Botrytis cinerea Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Botrytis cinerea IgG Ab [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
ALLERGY |
|
42591-8 |
|
|
|
|
Both |
|
|
|
0 |
B cinerea IgG-mCnc |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B cinerea; Immune globulin G; Immunoglobulin G; Level; m7; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
2.16 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
42592-6 |
Brucella abortus Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Brucella abortus IgG Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42592-6 |
|
|
|
|
Both |
|
|
|
0 |
B abortus IgG CSF Ql |
|
|
|
N |
|
Abort; ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B abortus; Bangs disease; Bovine brucellosis; Bruc; Brucellosis; Cerebral spinal fluid; Cerebrospinal Fl; Contagious abortion; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Undulant fever |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42593-4 |
Calcium |
SCnc |
BldC |
Pt |
Qn |
|
|
ACTIVE |
Calcium [Moles/volume] in Capillary blood |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
42593-4 |
|
|
|
|
Both |
|
|
|
0 |
Calcium BldC-sCnc |
|
|
|
N |
|
Blood - capillary; Ca; Cal; Cap bld; Cap blood; Capillary bld; Capillary blood; Chemistry; Finger stick; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.42 |
2.16 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
42594-2 |
Fraxinus americana Ab.IgE/IgE.total |
AFr |
Ser |
Pt |
Qn |
|
|
ACTIVE |
White Ash IgE Ab/IgE total in Serum |
|
MIN |
DefinitionDescription |
|
|
% response |
|
|
|
|
|
|
ALLERGY |
|
42594-2 |
|
|
|
|
Both |
|
|
|
0 |
White Ash IgE/IgE total % |
|
|
|
N |
|
%; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; IgE total; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; t015; t15; Tot; Total IgE; Totl; White ash |
2.7 |
2.16 |
|
|
|
|
|
|
|
%{response} |
|
|
The divisor /IgE.total has been added to this term to clarify that the denominator is the patient's total IgE, and Property has been corrected from Ratio to AFr. |
0 |
42595-9 |
Hepatitis B virus DNA |
ACnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Hepatitis B virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
42595-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HBV DNA SerPl NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HBV; Hep; Hep B; Hepatis; Hepatit; Hepatology; HepB; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.16 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
42596-7 |
Corticotropin^30M post XXX challenge |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --30 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
42596-7 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH 30M p chal Plas-mCnc |
|
|
|
N |
|
30M p chal; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; Tumor marker |
2.7 |
2.16 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
42597-5 |
Corticotropin^1.5H post XXX challenge |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
42597-5 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH 1.5h p chal Plas-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 90 min; 90 minutes; 90M; 90min; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; Tumor marker |
2.7 |
2.16 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
42598-3 |
Corticotropin^baseline |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --baseline |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
42598-3 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH BS Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; BS; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Tumor marker |
2.73 |
2.16 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
42599-1 |
Corticotropin^1H post XXX challenge |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --1 hour post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
42599-1 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH 1h p chal Plas-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p chal; 60 min; 60 minutes; 60M; 60min; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; Tumor marker |
2.7 |
2.16 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
426-7 |
Pyrazinamide |
Titr |
Isolate+Ser |
Pt |
SemiQn |
SBT |
|
ACTIVE |
Pyrazinamide [Susceptibility] by Serum bactericidal titer |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
ABXBACT |
|
426-7 |
|
SBT |
|
|
Observation |
|
|
|
0 |
PZA Titr SBT |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; PZA; Random; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
4260-6 |
FLUoxetine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
FLUoxetine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4260-6 |
|
|
|
|
Observation |
|
|
|
0 |
FLUoxetine Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; Point in time; Prozac; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |